Skip to main content
Clinical Trials/NCT05664945
NCT05664945
Active, Not Recruiting
N/A

Rethinking Pulmonary Rehabilitation for Patients With COPD: a Three-arm Randomised Multicentre Trial (REPORT-trial)

Copenhagen University Hospital, Hvidovre7 sites in 1 country180 target enrollmentJanuary 10, 2023

Overview

Phase
N/A
Intervention
pulmonary tele-rehabilitation (PTR)
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Copenhagen University Hospital, Hvidovre
Enrollment
180
Locations
7
Primary Endpoint
Change in COPD Assessment Test (CAT)
Status
Active, Not Recruiting
Last Updated
last month

Overview

Brief Summary

Pulmonary rehabilitation (PR) is one of the cornerstones of care for people with COPD together with smoking cessation and medical treatment. Despite the compelling evidence for its benefits, pulmonary rehabilitation is delivered to less than 30% of patients with COPD. Access to PR are particularly challenging, and especially for those with the most progressed stages of the disease.

Pulmonary Tele-rehabilitation (PTR) and Home-based pulmonary rehabilitation (HPR) are two emerging models using health-care supportive technology that have proven equivalent to the conventional PR programs in patients with COPD who are able and willing to participate in conventional PR.

However, much remain unknown regarding patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation. No studies have been conducted to specifically intervene towards this group. Response from emerging rehabilitation models for this specific group is a black box with no substantial research.

To fulfill its potential of relevance, results from emerging models, such as Pulmonary Telerehabilitation and Home-based pulmonary rehabilitation must be of clinical relevance, and superior to the current 'usual care' (medication and scheduled follow-up control) in patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation.

Detailed Description

This trial will investigate if pulmonary tele-rehabilitation (PTR) and home-based pulmonary rehabilitation (HPR) leads to respiratory symptom relief (CAT score) and improvements on secondary outcomes in patients unable to access conventional rehabilitation programs (standard PR offer). Our hypotheses in a three-arm RCT design are 1. PTR and HPR will be equivalent to each other 2. PTR and HPR will be superior to usual care, that is the control group (CON - no intervention)

Registry
clinicaltrials.gov
Start Date
January 10, 2023
End Date
July 31, 2027
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Copenhagen University Hospital, Hvidovre
Responsible Party
Principal Investigator
Principal Investigator

Henrik Hansen

Principal Investigator

Copenhagen University Hospital, Hvidovre

Eligibility Criteria

Inclusion Criteria

  • Indication for pulmonary rehabilitation according to Danish national guidelines
  • Unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation
  • A post-bronchodilator ratio FEV1/FVC \<70% (confirmed physician diagnosis of COPD)
  • A post-bronchodilator FEV1 \<80% (degree of airway obstruction) corresponding to GOLD grade 2-4 (moderate to very severe)
  • GOLD group B, C, D corresponding to severe respiratory symptoms and/or frequent acute exacerbations
  • Able to stand up from a chair (height 44-46cm) and walk 10 meters independently (with or without a walking aid)
  • Able to lift both arms to a horizontal level with a minimum of 1 kilogram's dumbbells in each hand

Exclusion Criteria

  • Participation in conventional PR in the past 24 months
  • Cognitive impairment - unable to follow instructions
  • Impaired hearing or vision - unable to see or hear instruction from a tablet
  • Unable to understand and speak Danish
  • Comorbidities where the exercise content is contraindicated (e.g. treatment for diabetic foot ulcer, active cancer treatment, life expectancy \<12-months)

Arms & Interventions

pulmonary tele-rehabilitation (PTR)

Recieve supervised PTR 2/weekly, session duration of 60 min; 35 min of exercise and 25min of patient education for 10-weeks (primary endpoint). Delivered from Hvidovre/Bispebjerg Hospital to groups of 4-6 patients who exercise at home and communicate via tablet-camera. After 10-weeks of PTR, participants are offered once weekly PTR for 60minuttes in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).

Intervention: pulmonary tele-rehabilitation (PTR)

home-based pulmonary rehabilitation (HPR)

HPR is an individual self-initiated home-based PR program. Patient goal is to achieve at least 20 min of self-initiated muscle-endurance based exercise 3days/weekly for 10-weeks (primary endpoint). The first session is a home visit by an experienced respiratory physiotherapist and with focus on establishment of exercise goals, formal exercise prescription and education. The home visit is followed by 1/weekly session for 10-weeks.The sessions is delivered from Hvidovre/Bispebjerg Hospital via tablet-camera or telephone call. After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).

Intervention: home-based pulmonary rehabilitation (HPR)

Control

Control group will receive usual care; medication, scheduled follow-up visit and possible phone contact with GP or the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.

Intervention: Control

Outcomes

Primary Outcomes

Change in COPD Assessment Test (CAT)

Time Frame: Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint)

Patient completed questionnaires that assess respiratory symptoms. Eight item questionaire with total score from 0-40 points.

Secondary Outcomes

  • Change in Handgrip strength (JAMAR)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change Brief Pain Inventory (BPI)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Program completion(at 10-weeks from baseline (primary endpoint); 75-weeks from baseline (secondary endpoint))
  • Change in 30seconds sit-to-stand test (30sec-STS)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change in Hospital Anxiety and Depression Scale (HADS)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change Multidimensional Fatigue Inventory (MFI-20)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Number of hospital admissions (respiratory related and all-cause)(at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Mortality (respiratory related and all-cause)(at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change in 1-minute sit-to-stand test (1-min-STS)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change in Short Physcial Performance Battery (SPPB)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Changes in objectively measured physical acitivity (50% of total sample)(Baseline; 10-weeks from baseline ( primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change in Euro Qol (EQ5D-3L)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Change Pittsburg Sleep Quality Index (PSQI)(Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))
  • Adverse events(at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint))

Study Sites (7)

Loading locations...

Similar Trials